Core Viewpoint - Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company focused on innovative treatments for cardiovascular diseases, with a presentation scheduled at the J.P. Morgan Healthcare Conference in January 2026 [1]. Company Overview - Lexeo Therapeutics is based in New York City and is dedicated to transforming heart health through advanced scientific approaches to treat cardiovascular diseases [3]. - The company is developing a portfolio of therapeutic candidates targeting genetic causes of conditions, including LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for plakophilin-2 arrhythmogenic cardiomyopathy, addressing significant unmet medical needs [3]. Event Details - R. Nolan Townsend, the CEO of Lexeo Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 AM PT in San Francisco, California [1]. - The presentation will be available via live webcast on the company's website, with a replay accessible afterward [2].
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference